- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 403/12
Total number of patents in this class: 9916
10-year publication summary
|
640
|
668
|
642
|
729
|
727
|
679
|
770
|
645
|
521
|
342
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4757 |
204 |
| Boehringer Ingelheim International GmbH | 4486 |
153 |
| F. Hoffmann-La Roche AG | 7808 |
134 |
| Novartis AG | 10173 |
122 |
| Janssen Pharmaceutica N.V. | 3160 |
103 |
| Hoffmann-La Roche Inc. | 3818 |
101 |
| BASF SE | 21306 |
99 |
| Vertex Pharmaceuticals Incorporated | 1579 |
92 |
| Pfizer Inc. | 3409 |
87 |
| Merck Sharp & Dohme LLC | 3737 |
85 |
| AstraZeneca AB | 2824 |
84 |
| Genentech, Inc. | 4114 |
83 |
| Merck Patent GmbH | 5735 |
82 |
| Takeda Pharmaceutical Company Limited | 2700 |
73 |
| Gilead Sciences, Inc. | 2236 |
72 |
| Bayer AG | 3522 |
61 |
| Amgen Inc. | 4440 |
58 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
58 |
| The Regents of the University of California | 20815 |
57 |
| Array BioPharma Inc. | 442 |
52 |
| Other owners | 8056 |